Dexamethasone

Generic Name: Dexamethasone

Brand Names: Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₉FO_₅

CAS Number: 50-02-2

Unique Ingredient Identifier: 7S5I7G3JQL

Background: Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.

Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.

Indication: Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes

Associated Therapies: -

Clinical Trials

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Phase 2

Recruiting

Conditions: COVID-19

Interventions: Drug: Remdesivir
Drug: Imatinib Mesylate
Drug: Dexamethasone
Biological: dornase alfa
Drug: Celecoxib
Biological: IC14
Biological: narsoplimab
Drug: Cenicriviroc
Drug: Apremilast
Drug: Icatibant
Drug: Cyproheptadine
Drug: Cyclosporine
Drug: Aviptadil
Drug: Famotidine

First Posted Date: 2020-07-27

Last Posted Date: 2024-03-19

Lead Sponsor: QuantumLeap Healthcare Collaborative

Target Recruit Count: 1500

Registration Number: NCT04488081

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
Sanford Health, Sioux Falls, South Dakota, United States
🇺🇸
University of Rochester Medical Center, Rochester, New York, United States

and more 33 locations

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Belantamab mafodotin
Drug: Pomalidomide
Drug: Dexamethasone
Drug: Bortezomib

First Posted Date: 2020-07-23

Last Posted Date: 2024-05-28

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 357

Registration Number: NCT04484623

Locations: 🇬🇧
GSK Investigational Site, Plymouth, United Kingdom

DEXTENZA Compared to Topical Steroid Therapy Prior to Cataract Surgery in Patients Who Receive Premium Intraocular Lenses

Phase 4

Completed

Conditions: Cataract

Interventions: Drug: Prednisolone Acetate 1% Oph Susp
Drug: Dexamethasone

First Posted Date: 2020-07-21

Last Posted Date: 2023-06-22

Lead Sponsor: Prism Vision Group

Target Recruit Count: 13

Registration Number: NCT04479748

Locations: 🇺🇸
Eye Associates of Vineland, Vineland, New Jersey, United States

Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19

Phase 2

Completed

Conditions: RNA Virus Infections
Coronavirus Infection
SARS (Severe Acute Respiratory Syndrome)
Virus Diseases
Coronaviridae Infections
Respiratory Tract Disease
Respiratory Tract Infections
Nidovirales Infections

Interventions: Drug: Dexamethasone
Drug: Tocilizumab

First Posted Date: 2020-07-20

Last Posted Date: 2024-05-31

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 453

Registration Number: NCT04476979

Locations: 🇬🇫
CH Andrée Rosemon, Cayenne, French Guiana

Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis

Phase 2

Conditions: Amyloidosis; Systemic

Interventions: Drug: Daratumumab
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2020-07-17

Last Posted Date: 2022-05-10

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 40

Registration Number: NCT04474938

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, China

Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)

Phase 3

Recruiting

Conditions: AVB - Atrioventricular Block
Fetal AVB

Interventions: Drug: Dexamethasone
Drug: IVIG

First Posted Date: 2020-07-16

Last Posted Date: 2024-05-20

Lead Sponsor: NYU Langone Health

Target Recruit Count: 1300

Registration Number: NCT04474223

Locations: 🇺🇸
University of California - Los Angeles (UCLA), Los Angeles, California, United States
🇺🇸
Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States
🇺🇸
UH Rainbow Babies / Children's Hospital, Cleveland, Ohio, United States

and more 21 locations

Assessing the Efficacy and Safety of DEXTENZA in Pseudo Phakic Patients Undergoing Gas Bubble Repair and Laser Following Retinal Detachment

Phase 4

Terminated

Conditions: Retinal Detachment

Interventions: Drug: Dextenza
Drug: Prednisolone Acetate

First Posted Date: 2020-07-09

Last Posted Date: 2023-08-16

Lead Sponsor: Midwest Eye Institute

Target Recruit Count: 7

Registration Number: NCT04464629

Locations: 🇺🇸
Midwest Eye Institute, Indianapolis, Indiana, United States

A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Active, not recruiting

Conditions: Plasma Cell Myeloma

Interventions: Drug: isatuximab SAR650984
Drug: Pomalidomide
Drug: Dexamethasone
Drug: Carfilzomib

First Posted Date: 2020-07-07

Last Posted Date: 2024-10-08

Lead Sponsor: Sanofi

Target Recruit Count: 586

Registration Number: NCT04458831

Locations: 🇺🇸
University of Arkansas Medical Sciences Site Number : 8400021, Little Rock, Arkansas, United States
🇺🇸
St. Joseph Heritage Healthcare Site Number : 8400008, Fullerton, California, United States
🇺🇸
University of California San Francisco (PARENT) Site Number : 8400009, San Francisco, California, United States

and more 127 locations